vs

Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $28.5M, roughly 1.2× Creative Media & Community Trust Corp). Creative Media & Community Trust Corp runs the higher net margin — -125.8% vs -304.2%, a 178.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 3.6%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -8.5%).

Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CMCT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.2× larger
RXRX
$35.5M
$28.5M
CMCT
Growing faster (revenue YoY)
RXRX
RXRX
+678.1% gap
RXRX
681.7%
3.6%
CMCT
Higher net margin
CMCT
CMCT
178.5% more per $
CMCT
-125.8%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-8.5%
CMCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CMCT
CMCT
RXRX
RXRX
Revenue
$28.5M
$35.5M
Net Profit
$-11.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
-125.6%
-304.8%
Net Margin
-125.8%
-304.2%
Revenue YoY
3.6%
681.7%
Net Profit YoY
-11.4%
39.6%
EPS (diluted)
$-3.89
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCT
CMCT
RXRX
RXRX
Q4 25
$28.5M
$35.5M
Q3 25
$26.2M
$5.2M
Q2 25
$29.7M
$19.2M
Q1 25
$32.3M
$14.7M
Q4 24
$27.5M
$4.5M
Q3 24
$28.6M
$26.1M
Q2 24
$34.4M
$14.4M
Q1 24
$34.0M
$13.8M
Net Profit
CMCT
CMCT
RXRX
RXRX
Q4 25
$-11.4M
$-108.1M
Q3 25
$-12.5M
$-162.3M
Q2 25
$-9.0M
$-171.9M
Q1 25
$-6.1M
$-202.5M
Q4 24
$-10.3M
$-178.9M
Q3 24
$-10.4M
$-95.8M
Q2 24
$-796.0K
$-97.5M
Q1 24
$-3.7M
$-91.4M
Gross Margin
CMCT
CMCT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
CMCT
CMCT
RXRX
RXRX
Q4 25
-125.6%
-304.8%
Q3 25
-47.7%
-3327.6%
Q2 25
-30.3%
-916.8%
Q1 25
-19.0%
-1297.9%
Q4 24
-128.8%
-4042.4%
Q3 24
-36.9%
-377.1%
Q2 24
-1.6%
-697.4%
Q1 24
-10.7%
-698.4%
Net Margin
CMCT
CMCT
RXRX
RXRX
Q4 25
-125.8%
-304.2%
Q3 25
-47.5%
-3135.3%
Q2 25
-30.3%
-894.2%
Q1 25
-18.9%
-1373.3%
Q4 24
-129.8%
-3935.5%
Q3 24
-36.3%
-367.5%
Q2 24
-2.3%
-676.6%
Q1 24
-11.0%
-662.4%
EPS (diluted)
CMCT
CMCT
RXRX
RXRX
Q4 25
$-3.89
$-0.17
Q3 25
$-23.52
$-0.36
Q2 25
$-18.94
$-0.41
Q1 25
$-20.73
$-0.50
Q4 24
$97.71
$-0.56
Q3 24
$-305.04
$-0.34
Q2 24
$-98.64
$-0.40
Q1 24
$-125.46
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCT
CMCT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$15.4M
$743.3M
Total DebtLower is stronger
$509.8M
$9.6M
Stockholders' EquityBook value
$265.4M
$1.1B
Total Assets
$859.2M
$1.5B
Debt / EquityLower = less leverage
1.92×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCT
CMCT
RXRX
RXRX
Q4 25
$15.4M
$743.3M
Q3 25
$17.3M
$659.8M
Q2 25
$27.8M
$525.1M
Q1 25
$19.8M
$500.5M
Q4 24
$20.3M
$594.4M
Q3 24
$18.5M
$427.6M
Q2 24
$29.3M
$474.3M
Q1 24
$21.3M
$296.3M
Total Debt
CMCT
CMCT
RXRX
RXRX
Q4 25
$509.8M
$9.6M
Q3 25
$527.8M
$11.9M
Q2 25
$535.6M
$14.2M
Q1 25
$512.7M
$16.4M
Q4 24
$505.7M
$19.0M
Q3 24
$478.3M
$20.5M
Q2 24
$485.1M
$22.9M
Q1 24
$472.8M
Stockholders' Equity
CMCT
CMCT
RXRX
RXRX
Q4 25
$265.4M
$1.1B
Q3 25
$281.9M
$1.0B
Q2 25
$287.1M
$919.1M
Q1 25
$293.0M
$933.9M
Q4 24
$304.5M
$1.0B
Q3 24
$321.0M
$524.6M
Q2 24
$351.1M
$584.4M
Q1 24
$369.9M
$401.2M
Total Assets
CMCT
CMCT
RXRX
RXRX
Q4 25
$859.2M
$1.5B
Q3 25
$871.8M
$1.4B
Q2 25
$885.0M
$1.3B
Q1 25
$882.3M
$1.3B
Q4 24
$889.6M
$1.4B
Q3 24
$868.0M
$726.5M
Q2 24
$891.2M
$775.9M
Q1 24
$887.5M
$557.8M
Debt / Equity
CMCT
CMCT
RXRX
RXRX
Q4 25
1.92×
0.01×
Q3 25
1.87×
0.01×
Q2 25
1.87×
0.02×
Q1 25
1.75×
0.02×
Q4 24
1.66×
0.02×
Q3 24
1.49×
0.04×
Q2 24
1.38×
0.04×
Q1 24
1.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCT
CMCT
RXRX
RXRX
Operating Cash FlowLast quarter
$5.8M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCT
CMCT
RXRX
RXRX
Q4 25
$5.8M
$-46.1M
Q3 25
$3.7M
$-117.4M
Q2 25
$-2.5M
$-76.4M
Q1 25
$1.2M
$-132.0M
Q4 24
$17.0M
$-115.4M
Q3 24
$10.3M
$-59.2M
Q2 24
$3.9M
$-82.2M
Q1 24
$1.6M
$-102.3M
Free Cash Flow
CMCT
CMCT
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
CMCT
CMCT
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
CMCT
CMCT
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons